Lyra Therapeutics (LYRA) Current Leases (2019 - 2025)

Lyra Therapeutics has reported Current Leases for 7 years, with the latest figure at $4.8 million in Q4 2025.

• On a quarterly basis, Current Leases rose 16.91% year-over-year to $4.8 million in Q4 2025; TTM through Dec 2025 was $4.8 million, a 16.91% increase from a year earlier, with the FY2025 full-year figure at $4.8 million, up 16.91% from the prior year.
• Current Leases was $4.8 million for Q4 2025 at Lyra Therapeutics, up from $4.7 million in the prior quarter.
• The five-year high for Current Leases was $5.4 million in Q4 2023, with the low at $654000.0 in Q3 2022.
• Average Current Leases over 5 years is $2.7 million, with a median of $1.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Current Leases slumped 37.83% in 2022, then jumped 250.81% in 2023.
• Over 5 years, Current Leases stood at $1.1 million in 2021, then surged by 44.23% to $1.5 million in 2022, then surged by 250.81% to $5.4 million in 2023, then fell by 24.16% to $4.1 million in 2024, then grew by 16.91% to $4.8 million in 2025.
• The last three Current Leases figures came in at $4.8 million (Q4 2025), $4.7 million (Q3 2025), and $4.6 million (Q2 2025), per Business Quant data.